Clinical Trials Study
Copyright ©The Author(s) 2021.
World J Gastroenterol. May 14, 2021; 27(18): 2219-2237
Published online May 14, 2021. doi: 10.3748/wjg.v27.i18.2219
Table 1 Characteristics of the patients in the placebo and active treated groups

Placebo
P valueActive treated
P value
Total
Females
Males
Total
Females
Males
n
55
47
8
109
85
24
Age, yr (median, range)38.5 (18-75)38.0 (18-73)47.0 (20-75)0.339.0 (18-73)40.0 (18-73)32.0 (21-65)0.07
IBS-D211920.74230120.4
IBS-C2218440328
IBS-M1210227234
IBS duration, yr15.5 ± 7.916.2 ± 8.015.0 ± 9.00.917.3 ± 8.916.8 ± 8.218.0 ± 9.20.9
Age at IBS onset, yr (median, range)20.0 (15-35)20.5 (16-35)19.0 (15-30)0.420.0 (15-36)20.0 (16-35)20 (15-33)0.6
IBS-SSS total score315.2 ± 77.1320.1 ± 77.8286.9 ± 69.30.5312.9 ± 82.0319.1 ± 77.3297.7 ± 82.00.4
Moderate symptoms1 (%)23 (42)17 (36)6 (75)0.0645 (41)30 (35)13 (54)0.1
Severe symptoms2 (%)32 (58)30 (64)2 (25)64 (59)55 (65)11 (46)